These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15219138)

  • 1. [Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].
    MMW Fortschr Med; 2004 Mar; 146(13):60. PubMed ID: 15219138
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
    Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
    Belcher G; Schernthaner G
    Diabet Med; 2005 Aug; 22(8):973-9. PubMed ID: 16026360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
    J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.
    Chalmers J; Hunter JE; Robertson SJ; Baird J; Martin M; Franks CI; Whately-Smith CR; Mariz S; Campbell IW
    Curr Med Res Opin; 2007 Aug; 23(8):1775-81. PubMed ID: 17712875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
    de Winter W; DeJongh J; Post T; Ploeger B; Urquhart R; Moules I; Eckland D; Danhof M
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):313-43. PubMed ID: 16552630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C
    Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
    MMW Fortschr Med; 2004 Jul; 146(29-30):48-9. PubMed ID: 15540563
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
    Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Bell DS; Dharmalingam M; Kumar S; Sawakhande RB
    Diabetes Obes Metab; 2011 Sep; 13(9):800-5. PubMed ID: 21477065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
    Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
    Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New rank order of antidiabetic drugs. Using glitazone before sulfonylurea drugs? (interview by Dr. Dirk Einecke)].
    Jacob S
    MMW Fortschr Med; 2007 Jan; 149(1-2):14. PubMed ID: 17632857
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
    Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
    Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
    Panikar V; Chandalia HB; Joshi SR; Fafadia A; Santvana C
    J Assoc Physicians India; 2003 Nov; 51():1061-4. PubMed ID: 15260389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.